NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis $16.88 -1.17 (-6.48%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$16.35▼$18.2150-Day Range$16.00▼$23.3552-Week Range$10.87▼$24.74Volume1.19 million shsAverage Volume1.37 million shsMarket Capitalization$1.82 billionP/E RatioN/ADividend YieldN/APrice Target$25.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get NovoCure alerts: Email Address NovoCure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside51.1% Upside$25.50 Price TargetShort InterestHealthy6.65% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.04Based on 12 Articles This WeekInsider TradingSelling Shares$13,856 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.34) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.74 out of 5 starsMedical Sector229th out of 910 stocksSurgical & Medical Instruments Industry28th out of 95 stocks 3.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNovoCure has only been the subject of 4 research reports in the past 90 days.Read more about NovoCure's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.65% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in NovoCure has recently decreased by 14.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 1.7 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for NovoCure this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,856.00 in company stock.Percentage Held by InsidersOnly 6.29% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NovoCure's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.34) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NovoCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About NovoCure Stock (NASDAQ:NVCR)NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesSeptember 6 at 5:19 PM | fool.comWhy NovoCure Stock Dived by 13% This WeekSeptember 5 at 1:13 PM | markets.businessinsider.comNovoCure Leadership Transition Signals Stability and Earns Buy RatingSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 5 at 2:47 AM | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Receives $25.50 Average Target Price from AnalystsSeptember 3, 2024 | marketwatch.comNovocure Longtime CEO Asaf Danziger Resigns, CFO Ashley Cordova Named SuccessorSeptember 3, 2024 | marketwatch.comNovocure Shares Drop 12% on Resignation of Longtime CEOSeptember 3, 2024 | finance.yahoo.comNovocure Announces Planned CEO TransitionSeptember 3, 2024 | msn.comNovocure names Ashley Cordova as CEOSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 2, 2024 | ca.finance.yahoo.comNVCR Jan 2025 145.000 callAugust 28, 2024 | finance.yahoo.comNovocure to Participate in 2024 Wells Fargo Healthcare ConferenceAugust 22, 2024 | ca.finance.yahoo.comNVCR Dec 2024 22.500 callAugust 20, 2024 | ca.finance.yahoo.comNVCR Sep 2024 10.000 callAugust 18, 2024 | finance.yahoo.comNovoCure Limited (NVCR)August 15, 2024 | finance.yahoo.comNVCR Mar 2025 20.000 put (NVCR250321P00020000)August 15, 2024 | msn.comAfter a 92% share price crash, is this a bargain basement growth stock?August 14, 2024 | finance.yahoo.comNovocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung CancerAugust 13, 2024 | ca.news.yahoo.comDoctors in India demand better security after shocking killingSee More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today9/07/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,453Year FoundedN/APrice Target and Rating Average Stock Price Target$25.50 High Stock Price Target$40.00 Low Stock Price Target$17.00 Potential Upside/Downside+51.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-207,040,000.00 Net Margins-30.67% Pretax Margin-25.66% Return on Equity-45.68% Return on Assets-14.59% Debt Debt-to-Equity Ratio1.81 Current Ratio6.46 Quick Ratio6.22 Sales & Book Value Annual Sales$549.96 million Price / Sales3.30 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book5.05Miscellaneous Outstanding Shares107,611,000Free Float100,842,000Market Cap$1.82 billion OptionableOptionable Beta0.71 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. William F. Doyle (Age 62)Executive Chairman Comp: $1.52MMr. Asaf Danziger (Age 58)CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 45)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 66)Chief Operating Officer Comp: $1.01MMr. Frank LeonardExecutive VP & President of Novocure OncologyProf. Yoram Palti M.D. (Age 86)Ph.D., Founder & CTO Comp: $282.51kDr. Moshe Giladi Ph.D. (Age 54)Chief Science Officer Ms. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)General Counsel Mr. Michael Puri (Age 55)Chief Human Resources Officer More ExecutivesKey CompetitorsNevroNYSE:NVROGlaukosNYSE:GKOSStevanato GroupNYSE:STVNBausch + LombNYSE:BLCOTransMedics GroupNASDAQ:TMDXView All CompetitorsInsiders & InstitutionsAlgert Global LLCSold 17,203 shares on 8/16/2024Ownership: 0.013%Alpha DNA Investment Management LLCBought 20,353 shares on 8/15/2024Ownership: 0.019%Point72 Hong Kong LtdBought 17,385 shares on 8/15/2024Ownership: 0.017%Millennium Management LLCBought 600 shares on 8/15/2024Ownership: 0.000%Point72 Asia Singapore Pte. Ltd.Bought 1,984 shares on 8/15/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions NVCR Stock Analysis - Frequently Asked Questions How have NVCR shares performed this year? NovoCure's stock was trading at $14.93 at the beginning of the year. Since then, NVCR stock has increased by 13.1% and is now trading at $16.88. View the best growth stocks for 2024 here. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) posted its quarterly earnings data on Thursday, July, 25th. The medical equipment provider reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.09. NovoCure's revenue for the quarter was up 19.3% compared to the same quarter last year. What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. Who are NovoCure's major shareholders? NovoCure's top institutional investors include Baillie Gifford & Co. (1.57%), Renaissance Technologies LLC (0.71%), Federated Hermes Inc. (0.69%) and Marshall Wace LLP (0.46%). Insiders that own company stock include William F Doyle, Wilhelmus Cm Groenhuysen, Ashley Cordova, W Anthony Vernon, Frank X Leonard, Pritesh Shah, Uri Weinberg, Ely Benaim, Asaf Danziger, Jeryl L Hilleman and Todd Christopher Longsworth. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC) and Viper Energy (VNOM). This page (NASDAQ:NVCR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
